Home Sectors Healthcare Recent Valuation: CryoLife (NYSE: CRY)

Recent Valuation: CryoLife (NYSE: CRY)

7
0
SHARE

CryoLife trades as part of the healthcare sector and trades as part of the medical devices industry. The company CEO is James Patrick Mackin. Cryolife Inc is engaged in medical device manufacturing and distribution and in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. It has two segments: Medical Devices and Preservation Services.

Previous Intraday Trading Performance:

The CRY stock showed a previous change of -3.09% with an open at 30.38 and a close of 29.47. It reached an intraday high of 30.38 and a low of 29.40.

SeekingAlpha:  Stocks To Watch: Strap In For Q3

Liquidity:

The stock has a market cap of $1.1b with 36.8m shares outstanding, of which the float is 33.0m shares. Trading volume reached 198,969 shares compared to its average volume of 143,766 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, CryoLife shares returned -8.14% and in the past 30 trading days it returned -13.83%. Over three months, it changed 0.41%. In one year it has changed 26.48% and within that year its 52-week high was 36.05 and its 52-week low was 16.80. CRY stock is 75.42% above its 52 Week Low.

Our calculations show a 200 day moving average of 25.67 and a 50 day moving average of 33.23. Currently CRY stock is trading 14.82% above its 200 day moving average.

SeekingAlpha:  Stocks To Watch: Strap In For Q3

Earnings:

The last annual fiscal EPS for the company was reported at 0.11 that ended on 31st of December 2017, which according to the previous close, that is a PE of 267.91. Based on 1 analyst estimate, the estimated EPS for the next quarter is 0.06. The TTM EPS is 0.31, which comes to a TTM PE of 95.06. Historically, the PE high was 267.91 and the PE low was 14.70. If the stock reached its PE low, that would represent a price of 4.56, which is a decrease of -84.54%.

The following are the last four quarter reported earnings per share:
06-30-2018:  0.10
03-31-2018:  0.02
12-31-2017:  0.11
09-30-2017:  0.08

Base on our calculations, the intrinsic value per share is 7.45, which means it may be overvalued by -295.63%

Indicators to Watch:

Based on the latest filings, there is 76.10% of institutional ownership. Short-interest is 806,157, which is 2.19% of shares outstanding. The short-interest ratio or days-to-cover ratio is 6.27. This stock has some short interest, but it may be normal and no cause for concern if long the position.

The current calculated beta is 0.61

SeekingAlpha:  CorVel reports Q1 results

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is -2.11%, return on assets is -1.16%, profit margin is -3.75%, price-to-sales is 6.10 and price-to-book is 4.12.

Company Scores:

All scores are out of six:
 1  :Valuation Score
 0  :Past Performance Score
 1  :Financial Strength Score
 4  :Future Growth Score
 0  :Dividend Score
 1  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.